The START Center for Cancer Research

Take a virtual tour of START Dublin—Ireland’s first and only dedicated early-phase oncology unit: https://lnkd.in/eFC7JM7W Located within Mater Misericordiae University Hospital in Dublin, this state-of-the-art facility features 8 treatment chairs, 3 exam rooms, and dedicated PK and pharmacy spaces, supported by central hospital labs. With more than 30,000 new cancer patients diagnosed annually in Ireland, START Dublin fills a critical gap in clinical research infrastructure by bringing early-phase trials closer to patients. Led by Dr. Austin Duffy, an internationally recognized oncologist with decades of research and clinical expertise, the unit combines world-class care with the operational strength of the global START network. If you’re looking to expand your trials into high-potential regions with proven teams and infrastructure, schedule a meeting with us to learn more about what START Dublin can offer: https://lnkd.in/e-m-GmQq #Oncology #ClinicalResearch #PatientAccess

START, the world’s largest early-phase cancer drug development network, is seeking Principal Investigators at three of our U.S. research sites: START Carolinas, START New Jersey, and START Dallas Fort-Worth. This unique opportunity allows you to lead early-phase clinical trials of novel cancer treatments, all within a community-based setting. At START, you’ll collaborate with dedicated teams of physicians, pharmacists, and nurses while partnering with leading pharmaceutical and biotech companies. You’ll also have the chance to contribute to groundbreaking research, with opportunities for publications and presentations at national and international conferences. What makes this role especially meaningful is the immediate impact you can have for patients and families—bringing new therapies closer to home while helping accelerate the discovery of tomorrow’s cancer treatments. At START, this is how we live our mission of Hope Through Access: ensuring that more patients and communities have the opportunity to benefit from innovative clinical trials. Previous early-phase clinical trial experience is not required. We’re looking for oncologists and hematologists who are eager to make a difference in the lives of patients. If you’re ready to advance your career while helping transform oncology research, explore our open positions today: START Carolinas: https://lnkd.in/eZJ7pJbs START New Jersey: https://lnkd.in/ecW9zxMQ START Dallas Fort-Worth: https://lnkd.in/eAYmtrJ9 #hiring #clinicalresearch #oncology #clinicaltrials

As the only dedicated early-phase clinical trial unit in the Republic of Ireland, START Dublin is transforming how quickly patients gain access to new therapies. With a world-class team led by Dr. Austin Duffy, streamlined study activation processes, and access to a large, underserved patient population, START Dublin is built to move fast without compromising quality. In a recent case study of a Phase 1 solid tumor trial, START Dublin went from greenlight to first patient dose in just three weeks and successfully enrolled 22 patients — many of whom had no remaining treatment options. This rapid startup and enrollment success highlights not only Ireland’s urgent unmet need, but also the strength of START’s centralized support and local expertise. If you’re planning your next oncology study, make START Dublin your partner of choice. Contact us today to explore how we can accelerate your trial in Europe: https://lnkd.in/gQxY5k8E #Oncology #ClinicalResearch #ClinicalTrials

Congratulations to FoRx Therapeutics and our team at START Midwest for dosing the first patient in the first-in-human clinical study of FORX-428, a next-generation PARG inhibitor targeting the DNA Damage Response in advanced solid tumors. The patient was dosed by Dr. Manish R. Sharma, Co-Director of Clinical Research at START Midwest and Principal Investigator for the study. The trial aims to bring new hope to patients whose cancers do not—or no longer—respond to current therapies like PARP inhibitors. As Dr. Sharma shared, "There is an unmet need to develop new therapies for advanced cancer patients with distinct DNA damage repair deficiencies or high replication stress. The PARG inhibitor, FORX-428, has a novel mechanism of action, and preclinical studies have shown it had impressive activity in cancers resistant to chemotherapy and PARP inhibitors." We’re proud to collaborate with FoRx on this clinical trial and advance therapies with the potential to change the treatment landscape for advanced cancer patients. Read the full press release: https://lnkd.in/ezfBX-Bj

In a recent Phase 1 breast cancer trial, START’s global network demonstrated unmatched coordination and scale, enrolling 33 patients across 7 research centers — with diverse access to eligible populations. With centralized processes, fast startup, and experienced investigators, we provide sponsors with scalable performance across every geography — without compromising quality. See how START’s site network can deliver strong enrollment results for your next early-phase oncology trial: https://lnkd.in/gQxY5k8E #oncology #clinicaltrials #clinicalresearch #breastcancer

New research published in JCO Oncology Practice highlights a game-changing approach to assessing performance status in patients with metastatic cancer—using wearable accelerometers to provide objective, reliable data on physical activity: https://lnkd.in/giGpMAMG The study found that patients who walked less than 1,200 meters per day had significantly higher 180-day mortality—proving that wearable devices can help refine trial eligibility and improve patient outcomes through better data. We're especially proud that four of the authors are principal investigators from the START network in Europe: Dr. Bernard Doger de Spéville, Dr. Daniel Morillo Giles, Dr. Victor Moreno, and Dr. Tatiana Hernández. Together, they’ve authored over 2,000 scientific publications— a true reflection of the depth of experience, innovation, and leadership driving our work across Spain. Read the article here: https://lnkd.in/giGpMAMG And learn how objective performance status (OPS) may help optimize clinical trial enrollment and deliver safer, more effective therapies to patients. #Oncology #ClinicalTrials #ClinicalResearch #PatientEnrollment

We’re excited to announce our new partnership with Advarra—a strategic move to enhance speed, quality, and patient safety as we significantly scale our global oncology site network. https://lnkd.in/e8SsfbPi   Through this collaboration, START is integrating Advarra’s regulatory and technology infrastructure—including IRB, IBC, OnCore CTMS, and eReg—across our Network. As we scale our network globally, these solutions will ensure we continue to deliver fast, predictable timelines, ensure regulatory compliance, and uphold the highest standards in patient safety and data integrity.    This is more than operational alignment—it’s about raising the bar for how clinical trials are conducted in oncology.    As our Chairman & CEO Nick Slack, MBE said, “By partnering with Advarra, we are building a truly interconnected ecosystem, leveraging the best technology and regulatory expertise in the industry, and adopting Advarra’s standardized workflows and integrated platforms will significantly enhance our operational efficiency, compliance, and quality—ensuring that we not only accelerate the delivery of breakthrough therapies to patients but also uphold the highest standards of patient safety."   Read the press release: https://lnkd.in/e8SsfbPi

Will you be in Berlin for #ESMO2025? The START team will be on-site sharing exciting updates—including our newest global locations, expanded capabilities, and novel approaches to accelerating early-phase oncology trials. This is your chance to connect with our Principal Investigators and Clinical Operations leaders to discuss your current or upcoming pipeline and how START can support your goals with speed, quality, and patient access. Let’s meet at ESMO: https://lnkd.in/em6QtFaS #oncology #clinicalresearch #clinicaltrials #drugdevelopment

Take a virtual tour of START Rioja—our newest early-phase oncology unit expanding access across Northern Spain! https://lnkd.in/ejz3sx6Q Located in Logroño and integrated within a public hospital system, START Rioja serves a population of over 4 million. The facility features 4 exam rooms, 8 treatment chairs, and a dedicated pharmacy and PK lab equipped with the latest research technology. Led by Dr. María de Miguel, a globally respected PI with decades of oncology experience, this site combines clinical excellence with the operational strength of the START global network. If you're looking to expand your trials into high-potential regions with proven teams and infrastructure, learn more about what START Rioja can offer: https://lnkd.in/eU3Hrcqr #ClinicalTrials #OncologyResearch #Oncology

In a recent Phase 1 study targeting SCLC, CNS, and NEC tumors, START enrolled 42 patients across 5 global sites, tackling some of the most challenging oncology indications — and doing so with speed and precision. From rare tumor expertise to nimble trial execution, our teams are committed to accelerating new options for patients who need them most. Explore what START can do for your oncology development program: https://lnkd.in/gQxY5k8E #oncology #clinicaltrials #patientenrollment #patientaccess